Inhaled Treprostinil for Pulmonary Arterial Hypertension
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will look at safety and tolerability of LIQ861 (treprostinil) inhalation powder in adults with pulmonary arterial hypertension (PAH, WHO Group 1) who switch from selexipag, a medicine taken by mouth, to treprostinil, a medicine breathed into the lungs.
Everyone who takes part will receive LIQ861. On the first study day, participants will stop taking selexipag and begin taking LIQ861 four times a day using a small handheld dry powder inhaler. The dose may be increased over time based on how well it is tolerated. Participants will take LIQ861 for 16 weeks.
The study will also look at whether switching to LIQ861 affects walking distance, a blood marker of heart strain, and symptoms reported by participants.
Are You a Good Fit for This Trial?
This trial is for adults with pulmonary arterial hypertension (PAH, WHO Group 1) who are currently taking selexipag by mouth and are able to switch to a new inhaled medication. Participants should be stable enough to safely stop selexipag and start the study drug.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants transition from oral Selexipag to inhaled Treprostinil (LIQ861) and take it four times a day using a handheld dry powder inhaler. The dose may be increased over time based on tolerance.
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments of walking distance, blood markers of heart strain, and symptoms.
What Are the Treatments Tested in This Trial?
Interventions
- LIQ861 (treprostinil) inhalation powder
Trial Overview
The study tests the safety of LIQ861, an inhaled form of treprostinil, in people with PAH who switch from oral selexipag. All participants will use a handheld dry powder inhaler four times daily for 16 weeks. The dose may be adjusted based on tolerance.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Liquidia Technologies, Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.